Loading…
American Shared Hospital Services
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -51.4% over 5Y.
today you would have $514.49▼ -48.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.11 | $3.19 | $2.38 | $2.93 | $2.37 | $2.22 | $2.44 | $2.38 | $2.60 | $3.35 | $1.84 | $2.81 | $2.77 | $2.73 | $2.66 | $2.82 | $2.95 | |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FBLGFibroBiologics, Inc. | $1.44 | — | 1.9x | — | -660.08% | $9.59M |
| SINTSintx Technologies, Inc. | $1.50 | — | 2.1x | — | -255.86% | $10M |
| BFRGBullFrog AI Holdings, Inc. | $0.54 | — | 1.4x | — | -130.71% | $10.01M |
| APUSApimeds Pharmaceuticals US, Inc. | $6.30 |
American Shared Hospital Services provides technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. It operates in two segments: Leasing and Direct Patient Service. The company leases nine Gamma Knife systems and one proton beam radiation therapy (PBRT) system; and provides planning, installation, reimbursement, and marketing support services. It also owns and operates two single-unit Gamma Knife facilities that provides radiosurgery services directly to the patient. The company markets its solutions to cancer treatment centers, health systems, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.
Company description provided by Yahoo Finance.
| P/E |
| 19.7x |
| — |
| 9.7x |
| 23.8x |
| 14.0x |
| 79.0x |
| — |
| 22.2x |
| 14.0x |
| 7.9x |
| 19.7x |
| — |
| — |
| — |
| 273.0x |
| 24.2x |
| 282.0x |
| — |
| P/S | 0.7x | 0.5x | 0.7x | 0.7x | 0.9x | 0.8x | 0.7x | 0.7x | 0.7x | 0.8x | 1.0x | 0.6x | 1.0x | 0.7x | 0.7x | 0.6x | 0.8x | — |
| P/B | 0.7x | 0.6x | 0.8x | 0.7x | 0.8x | 0.7x | 0.7x | 0.5x | 0.5x | 0.6x | 0.9x | 0.5x | 0.7x | 0.7x | 0.6x | 0.6x | 0.7x | — |
| EPS | -$0.23 | $0.33 | $0.10 | $0.21 | $0.03 | -$1.14 | $0.11 | $0.17 | $0.33 | $0.17 | -$0.28 | -$0.19 | -$0.07 | $0.01 | $0.11 | $0.01 | -$0.04 |
| Profit margin | 1.69% | -5.53% | 7.71% | 2.86% | 6.73% | 1.10% | -39.57% | 3.20% | 5.19% | 9.83% | 4.97% | -9.20% | -6.18% | -1.77% | 0.22% | 2.28% | 0.34% | — |
| ROE | 0.98% | -6.46% | 8.68% | 2.70% | 6.14% | 0.98% | -36.62% | 2.53% | 4.08% | 8.06% | 4.33% | -7.56% | -4.44% | -1.59% | 0.19% | 2.50% | 0.29% | -0.83% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Dividend growing 0.0% a year against a 7.0% required return, taken from the stock’s beta. The only method anchored on what the company pays rather than what it reports.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
2 methods answered, across 2 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+20.6% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| — |
| 9.7x |
| — |
| — |
| $9.51M |
| INABIn8bio Inc | $1.04 | — | 0.6x | — | -111.11% | $10.2M |
| XBIOXenetic Biosciences, Inc. | $3.98 | — | 1.2x | — | -47.04% | $9.33M |